Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alessia Anastasia
Observed names:
A. Anastasia,
Anastasia, Alessia
Institution:
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Observed institutions:
Mario Negri Institute for Pharmacological Research,
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
ORCID:
0000-0002-2404-4564
Observed ORCID:
0000-0002-2404-4564
OpenAlex ID:
A5083626189
Soluble stroma‐related biomarkers of pancreatic cancer
2018
·
Andrea Resovi
, Maria Rosa Bani
, et al.
·
EMBO Molecular Medicine
·
77
PDF
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
2021
·
Francesca Bizzaro
, Ilaria Fuso Nerini
, et al.
·
Journal of Hematology & Oncology
·
64
PDF
Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol
2018
·
Monica Marzagalli
, Roberta Manuela Moretti
, et al.
·
Scientific Reports
·
62
PDF
Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts
2021
·
F. Guffanti
, M F Alvisi
, et al.
·
British Journal of Cancer
·
46
PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
2022
·
Carmen Ghilardi
, Catarina Moreira-Barbosa
, et al.
·
Cancer Research
·
44
PDF
Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives
2024
·
Claudia Alberti
, Federica Rizzo
, et al.
·
Neurobiology of Disease
·
41
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
2022
·
Alessia Anastasia
, Giulia Dellavedova
, et al.
·
Molecular Cancer Therapeutics
·
34
PDF
Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot–Marie–Tooth type 2A
2023
·
Federica Rizzo
, Silvia Bono
, et al.
·
Cellular and Molecular Life Sciences
·
28
PDF
Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2
2015
·
Carmen Ghilardi
, Antonietta Silini
, et al.
·
Oncotarget
·
18
PDF
Charcot–Marie‐Tooth type 2A in vivo models: Current updates
2024
·
Elena Abati
, Mafalda Rizzuti
, et al.
·
Journal of Cellular and Molecular Medicine
·
9
PO-44 - Tissue factor pathway inhibitor-2 (TFPI-2) is cleaved by PRSS3: implication for tumor endothelial cells migration
2016
·
C. Ghilardi
, A. Anastasia
, et al.
·
Thrombosis Research
·
6
Tph2 gene deletion enhances amphetamine‐induced hypermotility: effect of 5‐ HT restoration and role of striatal noradrenaline release
2015
·
Mirjana Carli
, Chrysaugi Kostoula
, et al.
·
Journal of Neurochemistry
·
6
Stroma gene signature predicts responsiveness to chemotherapy in pancreatic ductal adenocarcinoma patient‐derived xenograft models
2025
·
Alessia Anastasia
, Laura Formenti
, et al.
·
Molecular Oncology
·
5
Investigating the role of serum NfL, FGF21, NCAM1 and GDF15 as disease biomarkers for Charcot-Marie-Tooth type 2A
2026
·
Elena Abati
, Domenica Saccomanno
, et al.
·
Scientific Reports
·
1
PDF
AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model
2026
·
Elisa Pagliari
, Alessia Anastasia
, et al.
·
Journal of Biomedical Science
·
1
PDF
Supplementary Data from The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
2023
·
Alessia Anastasia
, Giulia Dellavedova
, et al.
·
1
AAV9 gene therapy optimization for SMARD1/CMT2S: safety and long-term efficacy comparison of two vectors in a SMARD1 preclinical model
2026
·
Pagliari, Elisa
, Anastasia, Alessia
, et al.
·
Figshare
Data from The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
2023
·
Alessia Anastasia
, Giulia Dellavedova
, et al.
Supplementary Data from The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
2023
·
Alessia Anastasia
, Giulia Dellavedova
, et al.
PDF
Data from The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases
2023
·
Alessia Anastasia
, Giulia Dellavedova
, et al.
Data from PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
2023
·
Carmen Ghilardi
, Catarina Moreira-Barbosa
, et al.
Supplementary Data from PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
2023
·
Carmen Ghilardi
, Catarina Moreira-Barbosa
, et al.
Supplementary Data from PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
2023
·
Carmen Ghilardi
, Catarina Moreira-Barbosa
, et al.
Supplementary Table from PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
2023
·
Carmen Ghilardi
, Catarina Moreira-Barbosa
, et al.
Supplementary Table from PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer
2023
·
Carmen Ghilardi
, Catarina Moreira-Barbosa
, et al.
Show more works
View as search
Works count:
42
Citation count:
443
H-index:
9
I10-index:
9
Year
Topic
Type